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Objectives: Streptococcus pneumoniae has shown a great ability to develop efficacious mechanisms of resist-
ance to the main drugs for the treatment of pneumonia, such as b-lactams, macrolides and fluoroquinolones.
The present study aimed to compare the antipneumococcal activity of combinations of respiratory fluoroqui-
nolones with cephalosporins (either parenteral or oral) or protected penicillin versus the standard combinations
(i.e. a macrolide with a protected penicillin or cephalosporin) against 100 isolates with different susceptibilities
to macrolides and/or penicillin.
Methods: Chequerboard assays for all isolates and time–kill curves for nine isolates with different patterns of
susceptibility were performed. Synergy between antibiotics at serum peak concentrations was also determined.
Results: The combination of levofloxacin with ceftriaxone produced the highest rate of synergy (54/100),
mainly against macrolide-resistant strains (22/30). Antagonism was not observed for any tested combination
apart from clarithromycin with amoxicillin/clavulanic acid (22/100 isolates). Although the killing activities of all
antibiotics improved when they were tested in combination, synergy was observed only for some combinations
after 12 and/or 24 h. Serum concentrations were effective in inhibiting the growth of the tested strains.
Conclusions: Combinations of levofloxacin with parenteral cephalosporins were the most active among all the
tested combinations, while antagonism occurred when clarithromycin and amoxicillin/clavulanic acid were
tested.
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Introduction
Lower respiratory tract infections (LRTIs), particularly community-
acquired pneumonia (CAP), represent the major cause of death
among infectious diseases.1,2 Thus, there is a pressing need to
monitor the antimicrobial susceptibilities of the causative patho-
gens in order to provide proper treatment to patients.3
In adults, the most frequent pathogen isolated is Streptococcus
pneumoniae (25%–60%), thus it is mandatory to treat empirically
with an antibiotic with high activity against this pathogen.2,3
However, over the years, S. pneumoniae has shown a great
ability to develop efficacious mechanisms of resistance to the
main drugs for the treatment of LRTIs, such as b-lactams, macro-
lides and fluoroquinolones.4
Resistance to penicillin is considered extremely variable in
different geographical areas. In Italy, strains classified as resistant,
according to CLSI (formerly NCCLS) criteria (MIC.4 mg/L), are
rather infrequent.5,6 In contrast, the wide dissemination of resist-
ance to macrolides in many countries, particularly in the Mediter-
ranean and Asiatic regions, is quite alarming, reaching 30%–40%
in our geographical area. With regard to fluoroquinolones, the
development of resistance in S. pneumoniae represents a low-
impact phenomenon worldwide.7
Data from retrospective analyses of patients with bacterae-
mic pneumococcal pneumonia suggest that combination anti-
biotic therapy is associated with reduced mortality as
compared with that seen among those who receive monother-
apy only.8,9 Combinations of antibiotics are usually adopted
with the double aim of widening coverage and increasing anti-
bacterial activity, limiting the occurrence and spread of resistant
strains.10 A highly bactericidal antibiotic combination with excel-
lent tissue penetration, which does not lead to the emergence of
resistance, would be a major advantage in the treatment of
pneumococcal diseases, particularly for the most severe forms.
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Fluoroquinolones plus b-lactams are now recommended as
an alternative option to macrolides plus b-lactams in the
treatment of severe pneumonia by the latest international guide-
lines [Infectious Diseases Society of America (IDSA)/American
Thoracic Society (ATS), 2007].11 With respect to the standard
combinations (i.e. macrolides plus b-lactams) the use of
fluoroquinolones plus b-lactams may be synergistic against
pneumococci.
However, these recommendations are still not strongly
supported either by in vitro studies or by clinical prospective
comparisons between different combinations in the therapy of
severe CAP.
Among respiratory fluoroquinolones, levofloxacin has a
double route of administration (oral and intravenous) and a
good safety profile.12 Thus, in cases of severe CAP (i.e. patients
admitted to intensive care units or with very complicated infec-
tions), only levofloxacin is recommended in combination with a
b-lactam (a third-generation cephalosporin or a carbapenem)
as an alternative to standard combinations according to the
Italian guidelines.12 The use of moxifloxacin in CAP is rec-
ommended only when the other antibacterials commonly used
for initial treatment of CAP are considered inappropriate.12
Thus, in order to widen the knowledge on the potential use of
levofloxacin in combination therapy with b-lactams, it would
be interesting to evaluate its antibacterial activity in combination
with parenteral and/or oral b-lactams.
The present study aims to compare the antipneumococcal
activity of combinations of respiratory fluoroquinolones with
cephalosporins (either parenteral or oral) or protected penicillin
versus the standard combinations (i.e. a macrolide with a pro-
tected penicillin or cephalosporin).
Materials and methods
Microorganisms
S. pneumoniae strains isolated from respiratory infections in patients
attending the IRCCS Galeazzi Hospital (Milan, Italy) and nursing home
residences in the north area of Milan were included in the study. Accord-
ing to their patterns of resistance, they were divided into fully susceptible
(n¼50), macrolide resistant (n¼30) and penicillin non-susceptible with
MIC≥2 mg/L (n¼20). Only one isolate per patient was considered, in
order to avoid duplicates.
All isolates were stored in brain heart infusion broth containing 10%
(w/v) glycerol at 2808C until use.
Antibiotics
Levofloxacin, moxifloxacin, cefotaxime, clarithromycin, cefpodoxime, cef-
triaxone and amoxicillin/clavulanic acid as powders of stated potency
were used to prepare stock solutions.
The following combinations were evaluated against 100 strains of
S. pneumoniae with different patterns of susceptibility by the chequer-
board assay and time–kill curves. Fluoroquinolone plus b-lactam
combinations: levofloxacin and ceftriaxone; levofloxacin and cefotaxime;
levofloxacin and amoxicillin/clavulanic acid; levofloxacin and cefpodox-
ime; moxifloxacin and ceftriaxone; moxifloxacin and cefotaxime.
Standard combinations: clarithromycin and amoxicillin/clavulanic acid;
clarithromycin and ceftriaxone.
Besides determining multiples and sub-multiples of MICs to evaluate
the activity of the studied combinations, peak serum concentrations of
each antibiotic, chosen from the available literature were assessed:
5.29 mg/L levofloxacin;13 3.22 mg/L moxifloxacin;14 209 mg/L cefotax-
ime;15 11.23 mg/L amoxicillin/clavulanic acid;16 2 mg/L clarithromycin;17
2.18 mg/L cefpodoxime;18 and 260 mg/L ceftriaxone.19
Determination of MICs
MICs were determined by means of the microdilution broth method
(microwell method) in accordance with the CLSI criteria.5,20 Briefly,
serial 2-fold dilutions of a starting antibiotic concentration were inocu-
lated into wells of a microtitre plate containing cation-adjusted
Mueller–Hinton broth supplemented with 5% lysed horse blood, so
that each well contained 5×105 cfu/mL. The MIC was defined as the
lowest antibiotic concentration able to inhibit visible bacterial growth
after 18–20 h of incubation in ambient air at 378C.
Evaluation of synergy
Chequerboard assay
For each combination, a synergy test was performed in a 96-well micro-
titre plate containing two antimicrobial agents in 2-fold dilutions (2×MIC,
1× MIC, 1/2× MIC, 1/4× MIC and 1/8× MIC) dispensed in a chequerboard
fashion on the day of the assay. Suspensions with turbidities equivalent
to that of a 0.5 McFarland standard were prepared to yield final inocula
of 3–5×105 cfu/mL. MICs were read after overnight incubation.
Each test was performed in duplicate at the stated antimicrobial con-
centration. Growth and sterility controls were included in each plate.
For the first clear well in each row of the microtitre plate containing
both antimicrobial agents, the fractional inhibitory concentration (FIC)
was calculated and the sum of both FICs in each well was used to classify
the effects of combinations of antimicrobial agents as: synergistic, for FIC
indexes ≤0.5; no interaction, for FIC indexes .0.5–4; and antagonistic,
for FIC indexes .4.21
Time–kill curves
An inoculum of each strain was prepared from a 24 h culture on blood agar
plates, and then adjusted to a turbidity equivalent to that of a 0.5 McFar-
land standard (1×108 cfu/mL) in sterile saline. It was subsequently
diluted to a final cell concentration of 1–3×106 cfu/mL, which was con-
firmed by colony counts in agar plates, by addition of Mueller–Hinton broth
supplemented with lysed horse blood containing no antibiotic (growth
control). Each antibiotic was tested alone and the same amounts of anti-
biotics in combination at the stated concentrations.
Bacterial counts were performed at 0, 3, 6, 12 and 24 h of incubation
at 378C by plating aliquots of 10 and 100 mL after dilution in sterile saline
onto Columbia blood agar plates.
Synergy was defined as a 2 log10 decrease in colony count when the
combinations were compared with the bacterial count obtained at the
same timepoint with the most active single agent of the combination.
Indifference was defined as a ,10-fold change in colony count at each
timepoint by the combination compared with that by the most active
agent. Antagonism was defined as a .100-fold increase in colony
count at each timepoint by the combination compared with that by
the most active drug alone.22
Results
Antimicrobial activities of single drugs
MIC values were determined in order to classify each strain
according to its susceptibility pattern: susceptible; penicillin
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in Table 1. Penicillin-non-susceptible and macrolide-resistant
strains showed higher MIC values of cephalosporins than
penicillin- and macrolide-susceptible strains. Penicillin resistance
was associated with macrolide resistance in 15 strains.
Evaluation of synergy
Chequerboard assay
Results are shown in Figure 1. The combination of levofloxacin with
ceftriaxone produced the highest rate of synergy (54/100), mainly
against macrolide-resistant strains (22/30). Levofloxacin and
cefotaxime yielded synergy in 50% of the strains: 24/50 fully
susceptible; 16/30 macrolide resistant; and 10/20 penicillin non-
susceptible. Levofloxacin and cefpodoxime showed synergy
against 14/100 strains: 5/50 susceptible; 7/30 macrolide resistant;
and 2/20 penicillin non-susceptible. Antagonism was not observed
for any tested combination. Moxifloxacin and ceftriaxone showed
synergy against 41/100 strains: 20/50 susceptible; 13/30 macro-
lide resistant; and 8/20 penicillin non-susceptible. Synergy
between moxifloxacin and cefotaxime was observed against
16/50 susceptible strains, 12/30 macrolide-resistant strains and
11/20 penicillin-non-susceptible strains.
With regard to standard combinations, clarithromycin and cef-
triaxone yielded synergy against 19/100 strains: 10/50 fully suscep-
tible; 7/30 macrolide resistant; and 2/20 penicillin non-susceptible.
Synergy between clarithromycin and amoxicillin/clavulanic acid
was observed against only 10/100 strains (4/50 susceptible, 3/30
macrolide resistant and 3/20 penicillin non-susceptible). Moreover,
this combination was antagonistic against 22/100 strains. Antag-
onism was not observed for any other combination.
Thus, when pneumococcal strains were stratified according to
their susceptibility profiles, combinations of levofloxacin with
cefotaxime were the most active against fully susceptible
strains, while levofloxacin with ceftriaxone gave the highest
degree of synergy against macrolide-resistant S. pneumoniae.
Against penicillin-non-susceptible strains the activity of the com-
bination of levofloxacin and ceftriaxone was comparable to that
of moxifloxacin plus cefotaxime and higher than all other
combinations.
All the combinations were effective in inhibiting growth of the
tested S. pneumoniae strains at concentrations equal to half the
corresponding serum Cmax.
Time–kill curves
Three strains for each group were chosen for time–kill assays.
Results are summarized in Table 2, where interactions of each
combination are reported. Although the killing activities of all
antibiotics improved when they were tested in combination,
synergy was observed only after 12 and/or 24 h. However, differ-
ently from the chequerboard assay, synergy was mainly observed
against resistant strains rather than against susceptible strains.
Clarithromycin plus amoxicillin/clavulanic acid failed to result in
synergy against all the tested groups and, in some cases, inter-
action between the compounds yielded antagonistic activity. In
contrast, no antagonism was observed for combinations of fluor-
oquinolones with cephalosporins. Combinations of levofloxacin
and moxifloxacin with ceftriaxone or cefotaxime and of levofloxa-
cin plus cefpodoxime showed synergy when subinhibitory concen-
trations were tested, although they did not produce bactericidal
effects in all cases. Moxifloxacin plus cefotaxime and levofloxacin
plus amoxicillin/clavulanic acid showed indifference against fully
susceptible strains. Combination of clarithromycin and ceftriaxone
yielded synergy only against penicillin-non-susceptible strains.
Levofloxacin plus cefotaxime showed synergy against all types
of S. pneumoniae.
The antimicrobial activity of combinations with fluoroquinolones
at Cmax was notably enhanced when compared with that of single
agents, although failing to result in synergy. In particular, more
rapid killing was observed after 6 h by the combinations of levoflox-
acin and moxifloxacin with cefotaxime, ceftriaxone and cefpodox-
ime against penicillin-non-susceptible strains and susceptible
pneumococci. A similar trend was observed for ceftriaxone in
association with moxifloxacin and, to a lesser extent, with clarithro-
mycin. In contrast, the combination of clarithromycin with amoxicil-
lin/clavulanic acid did not improve killing, and, in some cases,
reduced it, resulting in antagonistic activity (data not shown).
Discussion
Fluoroquinolones plus b-lactams are now recommended as an
alternative option to macrolides plus b-lactams in the treatment
of severe pneumonia according to IDSA/ATS guidelines.11 In
some in vitro studies, combinations of fluoroquinolones with
b-lactams showed synergy against pneumococci, and a wider
spectrum of activity when compared with the standard
combinations (i.e. macrolides plus b-lactams).12 However,
these recommendations are still not supported by in vitro
studies or by clinical prospective comparisons between different
combinations.
It is possible to hypothesize a grading of efficacy for the
therapy of severe CAP as follows: a b-lactam plus a macrolide
is superior to monotherapy with a b-lactam, but comparable
to monotherapy with a quinolone. Combination of a quinolone
plus a b-lactam could be superior to the other options, with con-
sequent indication for the most severe cases.
Table 1. Susceptibility of S. pneumoniae to the tested antibiotics
MIC range (mg/L)
LVX MXF CLR CRO CTX AMC CPD
Susceptible (n¼50) 0.06–1 0.03–0.25 0.008–0.25 0.008–0.125 0.008–0.125 0.008–0.06 0.016–1
Macrolide resistant (n¼30) 0.5–2 0.06–0.5 2–512 0.016–4 0.016–4 0.016–8 0.125–8
Penicillin non-susceptible (n¼20) 0.5–2 0.06–0.125 0.03–512 0.016–4 0.016–4 2–16 4–16
LVX, levofloxacin; MXF, moxifloxacin; CLR, clarithromycin; CRO, ceftriaxone; CTX, cefotaxime; AMC, amoxicillin/clavulanic acid; CPD, cefpodoxime.
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In previous studies, combined therapy showed a better
outcome compared with monotherapy, particularly in bacterae-
mic pneumococcal pneumonia.10,22 However, there are some
concerns about potential antagonism between b-lactams and
macrolides, which are a matter of debate, since conflicting evi-
dence has been obtained in in vitro studies.23,24 In contrast,
more consistent data have been obtained in studies assessing
the activities of combinations involving fluoroquinolones and
b-lactams, particularly cephalosporins, both in vitro and in
vivo.25 – 29 However, most of the cited studies limited their obser-
vations to a few strains of pneumococci and did not compare
different combinations between them.
The present study was designed to compare the in vitro inter-
actions of combinations between respiratory fluoroquinolones
and b-lactams versus standard combinations.
Evidence from our study seems to suggest that combinations of
antipneumococcal fluoroquinolones with cephalosporins are the
most active against all phenotypes of S. pneumoniae, showing
synergy or indifference against all the tested strains, while with
combinations of b-lactams with a macrolide (i.e. clarithromycin) a
risk of antagonism exists, particularly in combination with amoxicil-
lin/clavulanic acid. Results obtained with the chequerboard assay
for a total of 100 strains of S. pneumoniae with different suscepti-
bility patterns were confirmed by time–kill assays for a restricted
number of strains with all the tested combinations.
The highest rate of synergy was found with the combination of
levofloxacin with ceftriaxone, which was particularly active against
macrolide-resistant pneumococci; the combination of levofloxacin
with cefotaxime was equally effective against the fully susceptible,
macrolide-resistant or penicillin-non-susceptible strains tested.
Interestingly, the two fluoroquinolones tested, chosen for their
well-known activity against respiratory pathogens, showed a
different rate of synergy with the parenteral cephalosporins.
Since the mechanism underlying the activity of antibiotics in com-
bination should be the same for levofloxacin and moxifloxacin, the
difference observed could be attributable to differences in intrinsic
activity of the two molecules. Synergy of levofloxacin with ceftriax-
one and cefotaxime has been previously reported in animal
models of meningitis caused by two penicillin-resistant pneumo-
cocci.26,27 In contrast to these studies, we observed synergy only
after 12 h of incubation. It is possible that this difference could
be due to the tested strains or to the difference in the bacterial
inocula used, which were 1 log higher in the studies of Cottag-
noud et al.27 than in our study.
According to the Italian guidelines, levofloxacin is recommended
for the therapy of severe CAP in combination with b-lactams.
After reaching clinical stability, sequential therapy, whenever poss-
ible, or switch therapy, is suggested for both drugs.10 With regard to
moxifloxacin, recently its labelling recommends its use in CAP only
when the other antibacterials commonly used for the therapy
of CAP are considered inappropriate. Moreover, the intravenous
form is still not available in Italy, further limiting its use in severe
CAP.12 Thus, only levofloxacin in combination with oral b-lactams











































































































































Figure 1. Activity of antimicrobial combinations against susceptible (a),
macrolide resistant (b) and penicillin non-susceptible (c) S. pneumoniae
(n¼100). Black bars, synergy; white bars, no interaction; diagonally
striped bars, antagonism. LVX, levofloxacin; MXF, moxifloxacin; CLR,
clarithromycin; CRO, ceftriaxone; CTX, cefotaxime; AMC, amoxicillin/
clavulanic acid; CPD, cefpodoxime.
Table 2. Time–kill activities of antimicrobial combinations against




12 h 24 h 12 h 24 h 12 h 24 h
CLR+AMC 0 0 7 5 2 4
CLR+CRO 1 2 8 7 0 0
LVX+AMC 4 6 5 3 0 0
LVX+CPD 7 9 4 3 0 0
LVX+CTX 5 5 4 4 0 0
LVX+CRO 5 8 4 1 0 0
MXF+CTX 0 5 9 4 0 0
MXF+CRO 1 7 8 3 0 0
LVX, levofloxacin; MXF, moxifloxacin; CLR, clarithromycin; CRO, ceftriaxone;
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Ceftriaxone showed superior activity compared with amoxicillin/
clavulanic acid in combinations with both levofloxacin and clari-
thromycin, although associations of ceftriaxone with a fluoroqui-
nolone were more active than combination with a macrolide.
Moreover, amoxicillin/clavulanic acid in combination with a
macrolide was the only antibiotic combination that yielded an
antagonistic effect against some pneumococci, thus confirming
the need to further investigate these results.
Synergy was also observed for the combination of levofloxacin
with cefpodoxime, but only in a few cases, while the two anti-
biotics acted substantially as individuals in their activity against
S. pneumoniae.
In conclusion, eight combinations of fluoroquinolones and a
macrolide with different b-lactams have been assessed against
S. pneumoniae strains with different patterns of susceptibility.
Combinations of levofloxacin with parenteral cephalosporins
were the most active among all the tested combinations, sup-
porting their important role as an alternative to the standard
combinations. Instead, antagonism occurred when clarithromy-
cin and amoxicillin/clavulanic acid were tested. Data from pro-
spective clinical trials are needed to evaluate the relevance of
our findings in clinical practice.
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